Skadden Arps Slate Meagher & Flom and Gibson Dunn & Crutcher have taken on lead roles in New Jersey-headquartered pharmaceutical group Merck & Co’s $3 billion acquisition of Eyebiotech, an ophthalmology-focused drug development company in the U.K.
It is the latest example of a U.S. business acquiring a U.K. company, a growing trend in U.K. M&A that is furnishing U.S. law firms with plenty of work.
